Tonix Pharmaceuticals Holding Corp
$ 19.53
9.84%
04 Dec - close price
- Market Cap 190,191,000 USD
- Current Price $ 19.53
- High / Low $ 20.03 / 17.74
- Stock P/E 0.06
- Book Value 22.73
- EPS 279.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE -0.65 %
- 52 Week High 130.00
- 52 Week Low 6.76
About
Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company headquartered in Chatham, New Jersey, dedicated to developing innovative treatments for central nervous system disorders and rare diseases. With a focus on addressing significant unmet medical needs in mental health and pain management, Tonix is advancing a diverse pipeline of proprietary drug candidates through various phases of clinical development. The company's strengths in drug formulation and delivery, along with its strategic emphasis on its clinical programs, position Tonix as a potential leader in the pharmaceutical landscape, poised for significant growth amid evolving healthcare demands.
Analyst Target Price
$67.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-22 | 2025-03-31 | 2024-11-07 | 2024-08-09 | 2024-05-13 | 2024-02-26 | 2023-11-09 | 2023-08-10 | 2023-05-08 | 2023-03-13 |
| Reported EPS | -3.6975 | -3.86 | -2.642 | -9.767 | -0.2288 | -19.28 | -0.18 | -0.86 | -1.83 | -2.68 | -3.25 | -0.56 |
| Estimated EPS | -3.31 | -6.83 | -3.09 | -3.91 | -2.93 | -3.27 | -0.39 | -1.64 | -1.49 | -2.75 | -3.03 | -0.86 |
| Surprise | -0.3875 | 2.97 | 0.448 | -5.857 | 2.7012 | -16.01 | 0.21 | 0.78 | -0.34 | 0.07 | -0.22 | 0.3 |
| Surprise Percentage | -11.7069% | 43.4846% | 14.4984% | -149.7954% | 92.1911% | -489.6024% | 53.8462% | 47.561% | -22.8188% | 2.5455% | -7.2607% | 34.8837% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNXP
2025-10-18 01:03:19
This article from Investing.com Philippines reports that Tonix Pharmaceuticals is advancing its mpox vaccine candidate, TNX-801. The company has presented promising data regarding TNX-801, suggesting progress in its development. However, the full content of the article is unavailable due to a client-side application error.
2025-10-17 23:52:32
The article reports an application error encountered while attempting to load content related to Tonix's mpox vaccine candidate TNX-801. Consequently, the actual content detailing Tonix's advancements and promising data for their mpox vaccine candidate is unavailable. The page displays a client-side exception message.
2025-10-17 22:39:57
The article reports on Tonix's mpox vaccine candidate, TNX-801, highlighting promising data. However, the provided content indicates an application error, suggesting the full article text is not available.
2025-10-17 11:57:22
The article reports an application error encountered while attempting to load content from au.investing.com. The requested news about Tonix advancing its mpox vaccine candidate TNX-801 could not be displayed. This indicates a technical issue preventing access to the article's full content.
2025-10-17 11:34:41
Tonix Pharmaceuticals (TNXP) presented promising data for its TNX-801 vaccine at the World Vaccine Congress-Europe 2025, highlighting its potential as a single-dose solution against orthopoxviruses like mpox and smallpox. Preclinical studies showed durable, robust immune responses and good tolerability. Despite strong financial health with no debt, the company faces profitability challenges and an Altman Z-Score indicating potential distress, although high insider ownership suggests confidence.
2025-10-17 11:33:10
The article indicates that Tonix Pharmaceuticals is advancing its mpox vaccine candidate, TNX-801, based on promising data. However, the full content of the article is not available due to a client-side error on the webpage.
